This Study will evaluate the effects of renal function on pharmacokinetics and safety of DA-8010
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Enrollment
33
DA-8010 5mg single dose administration
CHA Bundang Medical Center
Gyeonggi-do, South Korea
Area under the plasma concentration-time curve over the time interval from 0 to the last quantifiable plasma concentration (AUClast) of DA-8010
Time frame: Pre-dose, 1hour, 2hour, 3hour, 3.5hour, 4hour, 4.5hour, 5hour, 5.5hour, 6hour, 6.5hour, 7hour, 8hour, 12hour, 24hour, 48hour post-dosing on Day 1
Peak Plasma Concentration (Cmax) of DA-8010
Time frame: Pre-dose, 1hour, 2hour, 3hour, 3.5hour, 4hour, 4.5hour, 5hour, 5.5hour, 6hour, 6.5hour, 7hour, 8hour, 12hour, 24hour, 48hour post-dosing on Day 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.